AI in Healthcare

Today's Stories

1. 1

   Astellas adopts Boltz-2 NIM to speed up drug discovery

   Astellas Pharma has adopted NVIDIA's Boltz-2 NIM, an AI-powered platform that predicts biomolecular structures and binding affinity, to democratize and accelerate its drug discovery workflows. In a membrane-protein-targeted project, AI prioritization cut the number of compounds needing experimental evaluation to just 10, reducing assay count by over 90% and shortening the timeline to hit identification by over 70%. All 10 selected compounds showed the desired efficacy, validating the approach.

   The tool is already in company-wide use, with over 50 regular users and over 2,000 cumulative uses as of end of February 2026. Astellas plans to expand NIM deployment on Tokyo-1 with additional models like DiffDock, GenMol, and MolMIM for further democratization.

2. 2

   SORA Technology launches malaria elimination drones in Zanzibar

   SORA Technology has officially launched a malaria elimination project in Zanzibar, Tanzania, using satellite data, drones, AI, and a digital management platform. The project is funded by the Japanese government and implemented with WHO, ZAMEP, and IHI. Zanzibar has reduced malaria prevalence to 0.04%, making it one of the closest regions in Africa to eliminating the disease. However, finding and treating mosquito larvae sources in hard-to-reach areas remains a challenge, as traditional surveys take up to three days and require many people.

   The project deploys SORA's custom drone, TSUBASA, for targeted larvicide spraying, and uses the Zzapp Malaria Platform to manage mapping, spraying, progress, and effectiveness. Early operations are focused on the Kati district, with researchers from IHI monitoring mosquito population changes and comparing cost-effectiveness with traditional methods.

3. 3

   Cigna's AI push to save $200M, cut costs

   Cigna projects its AI and predictive analytics tools, used to identify chronic conditions like cancer and kidney disease, will save an estimated $200 million over the next three years by proactively connecting patients with clinicians. The company also announced a $100 million investment through 2028 to reduce clinician documentation time and speed up prescriptions. These savings are critical for Cigna, which generates $275 billion in annual revenue and ranks 14th on the latest Fortune 500 list, as national healthcare spending exceeds $5 trillion annually. A targeted campaign using AI insights led more than 80% of patients to opt for a biosimilar over a costly biologic, creating hundreds of millions in savings for patients.

   Cigna's AI chief emphasizes personalization and proactive care, and the company is partnering with major AI players like OpenAI and Anthropic. One deployed AI tool has reduced note-taking by up to 90% for practitioners in its telehealth service MDLIVE.

4. 4

   AI hearing glasses startup Legato emerges with $12M

   Legato, a hearing tech startup founded by two Bose veterans, emerged from stealth with $12 million in funding and a first look at its AI hearing glasses, called Legato Frames. The glasses are expected to launch later this fall. Legato targets people with mild to moderate hearing loss, the largest segment of the hearing-loss population. Its AI-powered system differentiates between background noise and voices, amplifying only the voices, aiming to make conversations clearer without the cognitively draining experience of some traditional hearing aids.

   Legato Frames will be available through select eye-care providers nationwide and will "cost a fraction" of traditional hearing aids. They may be eligible for vision insurance when purchased through an eye-care clinic.

5. 5

   Taiwan unveils AI-centric biotech growth plan

   Taiwan's Ministry of Economic Affairs outlined four strategies to scale up the island's biotech industry at a strategy meeting under the Executive Yuan on August 24. The plan centers on AI integration, stronger critical-drug supply chains, broader clinical validation, and deeper global market ties, which could enhance Taiwan's position in the biotech sector.

   The specifics of how these strategies will be implemented and their impact on Taiwan's biotech industry and global partnerships.

6. 6

   IHH CEO bets on preventive care as Asia ages

   IHH Healthcare, Asia's largest private health group, launched Healthspan, a preventive health and longevity program, in July. The program is currently available only in Singapore, but CEO Prem Kumar Nair hopes to expand it to IHH's nine other markets, including India, Turkey, and Greater China. Asia is aging rapidly—one in four people in the region will be older than 65 by 2050, and a Stanford study found that population aging accounted for 33.6% of the increase in disease burden across five key Asian economies. IHH is shifting from hospital-centric care to community-based ambulatory centers and clinical longevity programs to address this trend.

   IHH is building AI-enabled clinical pathways and has rolled out NurseShift.ai, which automates hospital rostering and won a health innovation award. The company is also considering expansion into Indonesia, which has changed regulations to allow full foreign ownership of private hospitals.